23 March 2017  
EMA/CHMP/824232/2016  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Zebinix 
eslicarbazepine acetate 
On 23 March 20017, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation of the medicinal product 
Zebinix. The marketing authorisation holder for this medicinal product is Bial - Portela & Cª, S.A. 
The CHMP adopted an extension to the existing indication for the tablet formulation as follows2: 
"Zebinix is indicated as: 
•  monotherapy in the treatment of partial-onset seizures, with or without secondary 
generalisation, in adults with newly diagnosed epilepsy; 
• 
adjunctive therapy in adults, adolescents and children aged above 6 years, with partial-onset seizures 
with or without secondary generalisation." 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold. 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
                                                
